Personalized Profiling of Pancreatic Tumors Using Biopsies and Organoid Technology to Improve Treatment

What this Trial Is About

Pancreatic ductal adenocarcinoma PDAC is a digestive cancer with the poorest outlook due to late diagnosis and limited treatment response. This research focuses on creating and validating patient-derived organoids from biopsy samples to enable personalized tumor analysis. The study aims to confirm that these organoids reflect the original tumors morphology, genetic features, and tumor marker expression, advancing personalized cancer care. The study involves patients undergoing an echo-endoscopic fine-needle biopsy EUS-FNB to collect pancreatic tumor samples. One to two biopsies will be used for regular diagnostic analysis, while an additional biopsy will be used to create organoids. This biopsy is split into three parts one for organoid culture, one preserved for genetic comparison, and one analyzed using innovative imaging technology Dynamic Full-field Optical Coherence Tomography. Blood samples will also be collected for genomic analysis. Participants will undergo standard EUS-FNB biopsy with an extra sample taken for research purposes. Researchers will evaluate organoid development over 8 weeks and assess their accuracy in replicating tumor features. Additional evaluations include protocol effectiveness over 3 months and imaging analysis on the first day. The study ensures careful monitoring of tumor characteristics and genetic profiles to support personalized treatment strategies.

Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)